Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 2
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 3(2)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05438407Phase 3Active Not Recruiting

Pediatric Patients Aged 4 to 11 Years With APDS

Role: collaborator

NCT06990529Phase 2Recruiting

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

Role: collaborator

NCT05693129Phase 3Active Not Recruiting

Pediatric Patients Aged 1 to 6 Years With APDS

Role: collaborator

NCT06604442Phase 4Completed

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Role: collaborator

All 4 trials loaded